Oct. 5 (Bloomberg) -- Bavarian Nordic A/S said its BN ImmunoTherapeutics subsidiary has agreed with the National Cancer Institute to jointly develop new off-the-shelf product candidates for the treatment of multiple cancers and a new technology platform based on NCI’s cancer vaccine technology.

Link to Statement:{NSN LSLLQ13V2800 <GO>}

To contact the editor responsible for this story: Christian Wienberg at cwienberg@bloomberg.net